Compare Incyte Corporation (INCY) vs Rent the Runway Inc (RENT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Rent the Runway Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Rent the Runway Inc trades at $3.59 (market cap $122.65M). The key difference: Incyte Corporation is far larger — about 200.1× Rent the Runway Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.
| INCY | RENT | |
|---|---|---|
Market Cap | $24.54B | $122.65M |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $9.39 |
52-Week Low | $81.61 | $3.01 |
Enterprise Value | $20.04B | $282.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Rent the Runway (RENT) trades at $3.60, down 1.1% on the day. The stock shows a bullish technical signal with positive moving averages, while fundamentals reveal a mixed picture: revenue grew to $306.20M in 2025 (company filing, 2025), but net losses persist at -$69.90M. Recent leadership changes, with Teri Bariquit appointed interim CEO (GlobeNewsWire, 2026-05-13), add a layer of transition. The company maintains a high gross margin of 73.81%, yet negative shareholder equity of -$182.50M signals significant financial leverage.
The outlook is cautiously optimistic. A low P/S ratio of 0.2 suggests potential undervaluation if the company can achieve projected profitability in 2026. However, high debt levels, consecutive annual net losses, and execution risks under new leadership pose substantial threats to shareholder value. Analyst sentiment is divided, with a 'Hold' bias reflecting this uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →
